Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prostate specific antigen test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    189 result(s) found for: Prostate specific antigen test. Displaying page 6 of 10.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    EudraCT Number: 2004-004874-96 Sponsor Protocol Number: HL/IDP/PTS/001 Start Date*: 2005-08-17
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Trust
    Full Title: Protocol: HL/IDP/PTS/001 Tumour Profiling In An Open-Labelled, 2-Arm Study Investigating The Tolerability And Efficacy Of Taxotere In Patients With High Risk Prostate Cancer
    Medical condition: Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001648-64 Sponsor Protocol Number: No EP-24332T-A014 Start Date*: 2004-09-16
    Sponsor Name:ardana LTD
    Full Title: A Phase II multicentre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix 90 mg, long-acting f...
    Medical condition: advanced prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000209-10 Sponsor Protocol Number: D8731C00002 Start Date*: 2020-10-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open-label Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination with Durvalumab and in Combination with Cabazitaxel and Durvalumab in Patients Who Have Progr...
    Medical condition: Progressive Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001787-36 Sponsor Protocol Number: 1333-GUCG Start Date*: 2015-09-14
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metas...
    Medical condition: Castration resistant prostate cancer patients metastatic to bone.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022111-19 Sponsor Protocol Number: FDC114615 Start Date*: 2010-11-22
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: Study FDC114615: Comparative efficacy of DuodartTM plus lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naïve men wi...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (Completed) FR (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005837-13 Sponsor Protocol Number: COU-AA-301 Start Date*: 2008-06-10
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Doceta...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer in Patients who have Failed Docetaxel-Based Chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed) GB (Completed) FR (Completed) DE (Completed) BE (Completed) HU (Completed) AT (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001128-38 Sponsor Protocol Number: pVAX/rhPSA -EP 2006 Start Date*: 2008-09-30
    Sponsor Name:Uppsala University Hospital
    Full Title: DNA Vaccine Coding for the Rhesus Prostate Specific Antigen (rhPSA) and Electroporation in Patients with Relapsed Prostate Cancer. A Phase I/II Study
    Medical condition: Patients with relapse of prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003968-56 Sponsor Protocol Number: CAAA617C12301 Start Date*: 2021-04-06
    Sponsor Name:Novartis Pharma AG
    Full Title: PSMAddition : An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patien...
    Medical condition: PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004705-31 Sponsor Protocol Number: RhoVac-001-FU Start Date*: 2021-04-26
    Sponsor Name:RhoVac ApS
    Full Title: Long-term follow-up study of immune response to vaccinations with RV001 in patients enrolled in RhoVac-001 study
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004730-42 Sponsor Protocol Number: IQVIA-ODYS-001-LZA45541 Start Date*: 2022-10-24
    Sponsor Name:IQVIA RDS FRANCE SAS
    Full Title: Prospective evaluation of potential effects of repeated gadolinium-based contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in c...
    Medical condition: Long term potential effect of repeated exposure to either a linear or a macrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 in motor and cognitive function among ne...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070999 Intraductal papillary mucinous neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 100000004871 10008953 Chronic liver disease LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002250-23 Sponsor Protocol Number: CBEZ235D2101 Start Date*: 2012-10-17
    Sponsor Name:Novartis Farmaceutica S.A.
    Full Title: Phase Ib dose finding study of abiraterone acetate plus BEZ235 or BKM120 in patients with castration-resistant prostate cancer
    Medical condition: patients with castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2006-004571-36 Sponsor Protocol Number: COU-AA-003 Start Date*: 2006-10-23
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
    Medical condition: Hormone refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004711-50 Sponsor Protocol Number: 9785-MA-1001 Start Date*: 2014-11-24
    Sponsor Name:Astellas Pharma Europe Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients...
    Medical condition: Metastatic Castrate Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) IT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) SE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) BE (Completed) FR (Completed) AT (Ongoing) PL (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021868-15 Sponsor Protocol Number: 9785-CL-0222 Start Date*: 2011-07-25
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer
    Medical condition: Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001161-27 Sponsor Protocol Number: EUOG2014-001 Start Date*: 2015-05-18
    Sponsor Name:European Uro- Oncology Group (EUOG)
    Full Title: An Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (MDV3100) Androgen Receptor (AR)-Directed Therapy in Chemo-Naïve patients with Progressive Prostate C...
    Medical condition: Chemo-Naïve patients with Progressive Prostate Cancer who have failed Androgen Deprivation Therapy (CRPC patients)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001144-22 Sponsor Protocol Number: HC1119-CS-03 Start Date*: 2021-02-22
    Sponsor Name:Hinova Pharmaceuticals (USA), Inc.
    Full Title: PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-Inferiority, Efficacy and Safety Study of Oral HC-1119 versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Medical condition: Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) NL (Ongoing) FI (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003227-20 Sponsor Protocol Number: ZD4054 Start Date*: 2007-09-27
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free...
    Medical condition: hormone-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10062904 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Prematurely Ended) DE (Completed) BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) NL (Completed) FR (Completed) PT (Completed) DK (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002271-17 Sponsor Protocol Number: 9785-CL-0410 Start Date*: 2014-02-25
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Multi-center, Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate
    Medical condition: Metastatic progressive castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004378-25 Sponsor Protocol Number: PC SOR-101 Start Date*: 2005-12-14
    Sponsor Name:Urologische Klinik und Poliklinik, Klinikum Großhadern der LMU München
    Full Title: A randomized, double-blinded, multicentric phase II trial to optimize the treatment of the hormon refractory prostatic carcinoma in patients without preceding chemotherapy with Sorafenib + Docetaxe...
    Medical condition: Locally progressed and / or metastasized hormon refractory prostate carcinoma
    Disease: Version SOC Term Classification Code Term Level
    10001203
    Population Age: Adults Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003713-11 Sponsor Protocol Number: 1938/2022 Start Date*: 2023-11-17
    Sponsor Name:Medical University of Vienna [...]
    1. Medical University of Vienna
    2. Medical University of Vienna
    Full Title: [177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with prostate cancer and biochemical but not radio-morphological local recurrence after primary therapy with curative intent: A Prospec...
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 06:45:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA